BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated ...

BioNTech founders plan exit to set up new venture, shares slump

By Ludwig Burger and Patricia Weiss FRANKFURT, March 10 (Reuters) - BioNTech's two co-founders and leading executives will leave the COVID-19 vaccine maker by the end of the year to start a new ...

BioNTech's Oncology Pipeline Advances Amid Financial Transition

As the European Lung Cancer Congress prepares to convene in Copenhagen, BioNTech SE is shifting investor focus toward its expanding oncology portfolio. New clinical data for its antibody-drug ...

BioNTech Shares Fall After Co-founders Plan Exit and Outlook Misses Forecasts

The stock was down 14% premarket after BioNTech announced the departures and issued revenue guidance that fell short of Wall ...

Co-founders behind pioneering Covid vaccine to step down from BioNTech

The co-founders of vaccine maker BioNTech are stepping down to launch a venture focused on next-generation messenger RNA technology, as the company reported a sharp increase in losses while seeking to ...

BioNTech stock tumbles as co-founders pivot to new mRNA venture

BioNTech SE BNTX shares are down during Tuesday’s premarket session as the company announced plans for its co-founders to transition into a new venture focused on next-generation mRNA innovations.

Is BioNTech (BNTX) Starting To Look Attractive After Recent Share Price Weakness

If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current ...
Morningstar

Pfizer and BioNTech: Slightly Lowering Our MRNA Vaccine Forecast Due to US Policy Headwinds

The US Food and Drug Administration’s Vinay Prasad issued a memo on Aug. 25 detailing the agency’s evolving thoughts on the coadministration of vaccines and approval requirements. A meeting of the ...
Fierce Biotech

Chutes & Ladders—BioNTech founders will depart to pioneer new company

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Biontech outlines €2B–€2.3B revenue target for 2026 while advancing late-stage oncology pipeline and leadership transition

Q4 2025 earnings call: 2026 revenue guidance, COVID vaccine outlook, oncology pipeline updates, and leadership transition—read now.
The Caledonian-Record

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio ...

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, ...

BioNTech SE: BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Presentations showcase progress in BioNTech's late-stage lung cancer programs, reinforcing the potential of the Company's differentiated portfolio spanning immunomodulators, antibody-drug conjugates, ...